Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/EUCTR2020-001049-38-NO
EUCTR2020-001049-38-NOActive, not recruitingPhase 1

A multi-center, randomized, double-blind, placebo-controlled, parallel group, phase III study to evaluate the efficacy and safety of LNP023 in primary IgA nephropathy patients

ovartis Pharma AG0 sites470 target enrollmentStarted: November 19, 2020Last updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditions

Trial Snapshot

Phase
Phase 1
Status
Active, not recruiting
Enrollment
470
Study OverviewEligibility CriteriaInvestigatorsRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional clinical trial of medicinal product

Eligibility Criteria

Sex
All

Inclusion Criteria

  • •Male and female patients = 18 years of age with an eGFR level and biopsy-confirmed IgA nephropathy as follows:
  • •For patients eGFR* = 45ml/min/1.73m2, a qualifying biopsy performed within the last 5 years is required
  • •For patients with eGFR* 30 to <45ml/min/1.73m2, a qualifying biopsy performed within 2 years with < 50% tubulointerstitial fibrosis is required.
  • •For patients with eGFR* 20 to <30ml/min/1.73m2, a qualifying biopsy performed at any time.
  • •In all cases, if a historical biopsy is not available, one may be performed during screening. *eGFR calculated using the CKD-EPI formula (or modified MDRD formula according to specific ethnic groups and local
  • •practice guidelines)
  • •Proteinuria due to primary diagnosis of IgA nephropathy as assessed at screening by UPCR =1 g/g (113 mg/mmol) sampled from FMV or 24h urine collection, as well as at the completion of the run-in period by
  • •UPCR =1 g/g (113 mg/mmol) calculated as the (geometric) mean of two 24h urine collections obtained within 14 days of each other at baseline
  • •Vaccination against Neisseria meningitidis and Streptococcus pneumoniae infection is required prior to the start of study treatment. If the patient has not been previously vaccinated, or if a booster is required, vaccine should be given according to local regulations at least 2 weeks prior to first study drug administration. If study treatment has to start earlier than 2 weeks post vaccination, prophylactic antibiotic treatment should be initiated.
  • •If not previously vaccinated, vaccination against Haemophilus influenzae infections should be given, if available and according to local regulations, at least 2 weeks prior to first study drug administration.
  • •All patients must have been on supportive care including stable dose regimen of ACEi or ARB at either the locally approved maximal daily dose or the maximally tolerated dose (per investigators' judgment) for
  • •approximately 90 days before first study drug administration. In addition, if patients are taking diuretics or other antihypertensive medication or other background medication for IgAN, the doses should also be stabilized for approximately -90 days prior to the first dosing of study treatment.
  • •Other protocol-defined inclusion criteria may apply.
  • •Are the trial subjects under 18? no
  • •Number of subjects for this age range:
  • •F.1.2 Adults (18-64 years) yes
  • •F.1.2.1 Number of subjects for this age range 456
  • •F.1.3 Elderly (>=65 years) yes
  • •F.1.3.1 Number of subjects for this age range 14

Exclusion Criteria

  • •Any secondary IgAN as defined by the investigator; secondary IgAN can be associated with cirrhosis, celiac disease, Human Immunodeficiency Virus (HIV) infection, herpetiformis, seronegative arthritis, small-cell
  • •carcinoma, lymphoma, disseminated tuberculosis, bronchiolitis obliterans, and inflammatory bowel disease, familial mediterranean fever, etc.
  • •Sitting office SBP >140 mmHg or DBP >90 mmHg at the randomization visit
  • •Patients previously treated with immunosuppressive or other immunmodulatory agents such as but not limited to cyclophosphamide, rituximab, infliximab, eculizumab, canakinumab, hydroxychloroquine,
  • •mycophenolate mofetil (MMF) or mycophenolate sodium (MPS), cyclosporine, tacrolimus, sirolimus, everolimus, or systemic corticosteroids exposure (>7.5 mg/d prednisone/prednisolone equivalent) within 90 days (or 180 days for rituximab) prior to first study drug administration. Participants previously or currently treated with oral budesonide. Participants treated with endothelin (receptor) antagonists within 90 days prior to first study drug administration
  • •Prior use of LNP023 or prior enrollment in any other LNP023 clinical trial where study drug was taken, including matching placebo
  • •History of recurrent invasive infections caused by encapsulated organisms, such as meningococcus and pneumococcus.
  • •Active systemic bacterial, viral (including COVID-19) or fungal infection within 14 days prior to study drug administration.
  • •Other protocol-defined exclusion criteria may apply.

Investigators

Similar Trials

Active, not recruiting
Not Applicable
A multi-center, randomized, double-blind, placebo-controlled, crossover study in women with irritable bowel syndrome to evaluate feasibility and reproducibility of barostat assessments of colorectal sensation during colorectal distention and its pharmacological modulation using octreotideIrritable Bowel SyndromMedDRA version: 9.1Level: PTClassification code 10023003Term: Irritable bowel syndrome
EUCTR2007-004994-25-GBovartis Pharma Services AG46
Active, not recruiting
Phase 1
A multi-center, randomized, double-blind, placebo-controlled phase III trial omparing the efficacy of bevacizumab in combination with rituximab and CHOP (RA-CHOP) versus rituximab and CHOP (R-CHOP) in previously untreated patients with CD20-positive diffuse large B-cell lymphoma (DLBCL) - MAIPreviously untreated patients with CD20-positive diffuse large B-cell lymphoma (DLBCL) who have low-intermediate, high-intermediate, or high-risk disease according to the IPI score and patients with bulky tumor (largest diameter = 7.5 cm) regardless of disease risk according to the IPI.MedDRA version: 8.1Level: LLTClassification code 10012818Term: Diffuse large B-cell lymphoma
EUCTR2006-005520-16-HUF. Hoffmann-La Roche Ltd1,060
Active, not recruiting
Not Applicable
A multi-center, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of 24 weeks treatment with vildagliptin in type 2 diabetes mellitus patients = 70 years (drug-naive or inadequately controlled on oral agents).
EUCTR2010-022658-18-DEovartis Pharma Services AG280
Active, not recruiting
Not Applicable
A multi-center, randomized, double-blind, placebo-controlled clinical trial to evaluate the effect of 52 weeks treatment with vildagliptin on left ventricular function in patients with type 2 diabetes and congestive heart failure.Type 2 Diabetes
EUCTR2008-005012-41-CZovartis Pharma Services AG246
Active, not recruiting
Not Applicable
Efficacy and safety of iron chelation therapy with deferasirox compared toplacebo in patients with myelodysplastic syndromes and transfusional ironoverload
EUCTR2009-012418-38-DKovartis Pharma Services AG210